Health
Johnson & Johnson’s Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun – The Motley Fool
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Johnson & Johnson(NYSE:JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2.
In contrast to other coronavirus vaccine candidates — such as the one many observers view as the most promising, Moderna’s mRNA-1273 — Johnson & Johnson’s produced its respo…
-
Noosa News16 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News18 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General15 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win
-
General22 hours agoOne person dead after house fire in Melbourne’s south-east